Sign in3 stories
CAMP4 plans to launch its first-in-human Phase 1/2 trial of CMP-002 in the fourth quarter of 2026 after clearing regulators in two countries, with cash extended into 2028.
SEC filing
The Cambridge biotech will use the proceeds to advance CMP-002, its SYNGAP1-related disorder therapy, following Australian clearance to begin a Phase 1/2 trial.
SEC filing
The clearance also triggers a second $50 million financing tranche tied to a September 2025 private placement, with closing expected August 3, 2026.
SEC filing